OLMA Olema Pharmaceuticals, Inc.: institutional ownership and insider trading
191 funds reported holding $1.48B of Olema Pharmaceuticals, Inc. in their latest 13F filings; in Q2 2026 funds net sold $25.4M, with 21 new positions and 37 funds selling out; over the last 12 months insiders bought $0 and sold $24.7M on the open market.
OLMA revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$63.2M, EPS -0.61
- Quarter ended Mar 31, 2026: revenue n/a, net income −$53.1M, EPS -0.52
- Quarter ended Dec 31, 2025: revenue n/a, net income −$46.1M, EPS -0.51
- Quarter ended Sep 30, 2025: revenue n/a, net income −$42.2M, EPS -0.49
Famous investors holding OLMA
- Stanley Druckenmiller (Duquesne Family Office): $12.3M, 0.2% of the portfolio
- Two Sigma (Two Sigma Investments): $14.2M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $9.08M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $695K, 0.0% of the portfolio
Largest institutional holders of OLMA
- FMR LLC — $152M
- Paradigm Biocapital Advisors LP — $108M
- JANUS HENDERSON GROUP PLC (JHG) — $106M
- VANGUARD GROUP INC — $89.0M
- Jupiter Topco LLC — $88.8M
- Bain Capital Life Sciences Investors, LLC — $88.6M
- BlackRock, Inc. (BLK) — $84.0M
- BVF INC/IL — $66.3M
- Siren, L.L.C. — $60.8M
- STATE STREET CORP (STT, STT-PG) — $54.0M
Recent OLMA insider trades
- Jul 24, 2026: Harmon Cyrus sold 25,000 shares ($291K)
- Mar 4, 2026: Mitchell Shawnte sold 40,000 shares ($952K)
- Jan 20, 2026: Harmon Cyrus sold 10,000 shares ($269K)
- Jan 15, 2026: Kovacs Shane William Charles sold 103,822 shares ($2.98M)
5%+ owners
- FMR LLC: 13.8% (Schedule 13G/A, filed Aug 6, 2026)
- BVF PARTNERS L P/IL: 9.8% (Schedule 13D/A, filed Oct 16, 2026)
- JANUS HENDERSON GROUP PLC: 8.2% (Schedule 13G/A, filed May 15, 2026)
- Bain Capital Life Sciences Opportunities IV, L.P.: 8.2% (Schedule 13G/A, filed May 15, 2026)
- BlackRock, Inc.: 7.1% (Schedule 13G/A, filed Jul 29, 2026)
- Raymond Debbane: 5.1% (Schedule 13G, filed Mar 20, 2026)